ARTELO BIOSCIENCES, INC. Increase (Decrease) in Accrued Liabilities
ARTELO BIOSCIENCES, INC. (ARTL) reported Increase (Decrease) in Accrued Liabilities of $15.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-12
- ARTELO BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$15.00K, a 250.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $30.00K.
- ARTELO BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $36.00K.
- ARTELO BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-06-30 was $10.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $15.00K 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $30.00K 10-Q · filed 2026-05-14 | |||
| 2025-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $46.00K derived: sum of 2 quarters · filed 2026-08-12 | $46.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $10.00K 10-Q · filed 2026-08-12 | $18.00K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | |||
| 2017-05-31 | $756.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-07-13 | $1.60K 10-Q · filed 2018-07-13 | ||
| 2017-02-28 | $847.00 10-Q/A · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |